Immucell (ICCC) Land & Improvements (2015 - 2016)
Immucell's (ICCC) quarterly Land & Improvements came in at $348827.0 in Q1 2016, up 4.6% on a QoQ basis from $333486.0 in Q4 2015.
Immucell (ICCC) Land & Improvements (2015 - 2016) Analysis & Trends
Immucell (ICCC) has 2 years of Land & Improvements data on file, last reported at $348827.0 in Q1 2016.
- Quarterly Land & Improvements changed N/A year-over-year to $348827.0 in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $348827.0 (changed N/A YoY) and the FY2015 annual result came in at $333486.0, changed N/A from the prior year.
- Land & Improvements climbed to $348827.0 in Q1 2016, from $333486.0 in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $348827.0 in Q1 2016 to a low of $333486.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 348,827.00 |
| Dec 31, 2015 | 333,486.00 |